Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer

Pancreas

Volumn 26, Issue 1, 2003, Pages 49-55

  Akashi, Tetsuro ^a   Oimomi, Hideki ^b   Nishiyama, Ken ichi ^a   Nakashima, Manabu ^b   Arita, Yoshiyuki ^a   Sumii, Toshihiko ^c   Kimura, Toshinari ^d   Ito, Tetsuhide ^a   Nawata, Hajime ^a   Watanabe, Takeshi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d Nakabaru Hospital   (Japan)

Author keywords

CA19 9; Chronic pancreatitis; Pancreatic cancer; RCAS1; SFasL; Tumor marker

Indexed keywords

BIOTIN; CA 19-9 ANTIGEN; FAS LIGAND; MONOCLONAL ANTIBODY; RCAS1 ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CHRONIC PANCREATITIS; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING;

AGED; ANTIGENS, NEOPLASM; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS;

EID: 0037216504     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200301000-00009     Document Type: Article

References (42)

1. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464-84.
2. Duffy MJ. CA19-9 as a marker for gastrointestinal cancers: A review. Ann Clin Biochem 1998;35:364-70.
3. Safi F, Beger HG, Bittner R, et al. CA19-9 and pancreatic adenocarcinoma. Cancer 1986;57:779-83.
4. Nitecki SS, Sarr MG, Colby TV, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221:59-66.
5. Warshaw AL, Swanson RS. Pancreatic cancer in 1988. Possibilities and probabilities. Ann Surg 1988;208:541-53.
6. van Gulik TM, Reeders JW, Bosma A, et al. Incidence and clinical findings of benign, inflammatory disease in patients resected for presumed pancreatic head cancer. Gastrointest Endosc 1997;46:417-23.
7. Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol 1990:85:350-5.
8. Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110:704-9.
9. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999;5:938-42.
10. Sonoda K, Nakashima M, Kaku T, et al. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 1996;77:1501-9.
11. Iwasaki T, Nakashima M, Watanabe T, et al. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int J Cancer 2000;89:488-93.
12. Takahashi H, Iizuka H, Nakashima M, et al. RCAS1 antigen is highly expressed in extramammary Paget's disease and in advanced stage squamous cell carcinoma of the skin. J Dermatol Sci 2001:26:140-4.
13. Sonoda K, Kaku T, Kamura T, et al. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasia. Clin Cancer Res 1998;4:1517-20.
14. Elnemr A, Ohta T, Yachie A, et al. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand: A potential mechanism for immune escape. Int J Oncol 2001;18:33-9.
15. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-I/CD95) ligand: Implications for tumor immune escape. Science 1996;274: 1363-6.
16. O'Connell J, O'Sullivan GC, Collins JK, et al. The Fas counterattack: Fasmediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
17. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nat Med 1996;2:1361-6.
18. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-12.
19. Shiraki K, Tsuji N, Shioda T, et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A 1997;94:6420-5.
20. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-83.
21. Kato K, Ohshima K, Ishihara S, et al. Elevated serum soluble Fas ligand in natural killer cell proliferative disorders. Br J Haematol 1998;103:1164-6.
22. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996;56:3870-4.
23. Nagao M, Nakajima Y, Hisanaga M, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 1999;30:413-21.
24. Das H, Imoto S, Murayama T, et al. Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br J Haematol 1999;104:795-800.
25. Tsutsumi S, Kuwano H, Shimura T, et al. Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 2000;89:2560-4.
26. Bellone G, Smime C, Carbone A, et al. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. Clin Cancer Res 2000;6:2448-55.
27. Kloppel G, Solcia E, Longnecker DS, et al., eds. Histological Typing of Tumours of the Exocrine Pancreas. 2nd Ed. Berlin: Springer, 1996.
28. Sobin LH, Wittekind Ch, eds. UICC TNM Classification of Malignant Tumours. 5th Ed. New York: John Wiley & Sons, 1997.
29. Noguchi K, Enjoji M, Nakamuta M, et al. Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma. Cancer Lett 2001;168:197-202.
30. Sonoda K, Nakashima M, Saito T, et al. Establishment of a new human uterine cervical adenocarcinoma cell line, SiSo, and its reactivity to anti-cancer reagents. Int J Oncol 1995;6:1099-104.
31. Kanda Y, Tanaka Y, Shirakawa K, et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant 1998;22:751-4.
32. Evans JD, Morton DG, Neoptolemos JP. Chronic pancreatitis and pancreatic carcinoma. Postgrad Med J 1997;73:543-8.
33. Uchida K, Okazaki K, Konishi Y, et al. Clinical analysis of autoimmune-related pancreatitis. Am J Gastroenterol 2000;95:2788-94.
34. Nakamoto Y, Sakahara H, Higashi T, et al. Autoimmune pancreatitis with F-18 fluoro-2-deoxy-D-glucose PET findings. Clin Nucl Med 1999;24:778-80.
35. Kimura W, Sasahira N, Yoshikawa T, et al. Duct-ectatic type of mucin producing tumor of the pancreas - New concept of pancreatic neoplasia. Hepatogastroenterology 1996;43:692-709.
36. Rickaert F, Cremer M, Deviere J, et al. Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients. Gastroenterology 1991;101:512-9.
37. Pour PM, Konishi Y, Kloppel G, et al. Atlas of Exocrine Pancreatic Tumors. Budapest: Springer, 1994:43-66.
38. Fukushima N, Mukai K, Sakamoto M, et al. Invasive carcinoma derived from intraductal papillary-mucinous carcinoma of the pancreas: Clinicopathologic and immunohistochemical study of eight cases. Virchows Arch 2001;439:6-13.
39. Traverso LW, Peralta EA, Ryan JA Jr, et al. Intraductal neoplasms of the pancreas. Am J Surg 1998;175:426-32.
40. Cellier C, Cuillerier E, Palazzo L, et al. Intraductal papillary and mucinous tumors of the pancreas: Accuracy of preoperative computed tomography, endoscopic retrograde pancreatography, and endoscopic ultrasonography and long-term outcome in a large surgical series. Gastrointest Endosc 1998;47:42-9.
41. Zamora C, Sahel J, Cantu DG, et al. Intraductal papillary or mucinous tumors (IPMT) of the pancreas: Report of a case series and review of the literature. Am J Gastroenterol 2001;96:1441-7.
42. Plate JM, Shott S, Harris JE. Immunoregulation in pancreatic cancer patients. Cancer Immunol Immunother 1999;48:270-9.